source
- Scribe Therapeutics’ early-stage IPO surges 43% as epigenetic cholesterol drug enters clinicScribe Therapeutics filed for an IPO while its lead epigenetic therapy moves into early clinical testing, a rare combination in a market that prefers later-stage, de-risked offerings. The company…
- Layoffs hit over 1,300 workers across seven biopharma M&A deals in 2026Workforce reductions this year have affected at least seven biopharma companies that recently completed mergers or acquisitions, eliminating a minimum of 1,359 jobs, according to BioSpace data. Th…